Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
Type:
Grant
Filed:
February 12, 2018
Date of Patent:
April 21, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Thomas J. Kipps, George F. Widhopf, II, Bing Cui
Abstract: Methods are provided for quantifying the fibroblast growth factor receptor 2 protein (FGFR2) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. The biological sample may be selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells. A protein sample is prepared from the biological sample and the FGFR2 protein is quantitated in the sample using the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one fragment peptide derived from FGFR2.
Type:
Grant
Filed:
May 16, 2016
Date of Patent:
April 14, 2020
Assignee:
Expression Pathology, Inc.
Inventors:
David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
April 7, 2020
Assignee:
ImmunoGen, Inc.
Inventors:
Christina N. Carrigan, Olga Ab, Daniel Tavares, Beni B. Wolf
Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
March 3, 2020
Assignees:
AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Inventors:
Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring osmolarity. Biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest. Model cells expressing the biosensors can be contacted with putative bioactive agents to determine possible activities, including as detectors of which is pH changes, as TempoOsmo™ accomplishes.
Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer.
Type:
Grant
Filed:
April 5, 2019
Date of Patent:
January 21, 2020
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Jeffrey Charles Way, Avram Lev Robinson-Mosher
Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
Abstract: Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.
Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Type:
Grant
Filed:
July 10, 2015
Date of Patent:
December 24, 2019
Assignee:
GENMAB A/S
Inventors:
Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Type:
Grant
Filed:
February 7, 2019
Date of Patent:
December 10, 2019
Assignee:
GENMAB A/S
Inventors:
Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
Type:
Grant
Filed:
April 21, 2017
Date of Patent:
December 10, 2019
Assignees:
Acceleron Pharma Inc., Adimab, LLC
Inventors:
John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
December 3, 2019
Assignee:
Kiniksa Pharmaceuticals, Ltd.
Inventors:
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
Abstract: Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form.
Type:
Grant
Filed:
July 14, 2014
Date of Patent:
November 26, 2019
Assignee:
HANMI PHARM. CO., LTD
Inventors:
Sung Hee Park, Min Young Kim, Hyung Kyu Lim, Sung Min Bae, Sung Youb Jung, Se Chang Kwon
Abstract: Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.
Abstract: The invention concerns isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2, whereby the antibodies bind additional CCR3-binding chemokines. The invention further concerns use of these antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.
Abstract: The present invention relates to a novel method for identifying pairs of receptors/ligands, transgenic animals useful for carrying out said method, and the use of ligands and/or modulators of the interaction between a ligand and its receptor in the food industry, fragrance industry, and health industry, for instance.
Type:
Grant
Filed:
August 25, 2015
Date of Patent:
November 12, 2019
Assignee:
UNIVERSITE DE GENEVE
Inventors:
Ivan Rodriguez, Alan Jacques Henri Cyrus Carleton, Daniel Rossier
Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
Type:
Grant
Filed:
October 5, 2015
Date of Patent:
November 5, 2019
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Wayne A. Marasco, Chen Xu, De-Kuan Chang
Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
October 29, 2019
Assignee:
Corixa Corporation
Inventors:
Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath